Drugs / NX210c
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05827653 | Dec 2022 → Apr 2023 | — | Axoltis Pharma | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT06365216 | Oct 2024 → Feb 2026 overdue | amyotrophic lateral sclerosis | Axoltis Pharma | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 13
| Date | Issuer | Release |
|---|---|---|
| 2026-09-15 | Axoltis Pharma | Results Axoltis Pharma announces topline Phase 2 results for NX210c in Amyotrophic Lateral Sclerosis axoltis.com ↗
Results support continuation of NX210c clinical development |
| 2026-06-24 | Axoltis Pharma | Results ENCALS 2026 – European Network to Cure ALS axoltis.com ↗
Preliminary Results Presented by Dr Emilien Bernard, Hospices Civils de Lyon, Coordinating Investigator of SEALS study, during TRICALS Satellite at the ENCALS meeting: insights in recent and upcoming trial results. |
| 2026-01-03 | Axoltis Pharma | Results SEALS Second DSMB Positive Review axoltis.com ↗
Axoltis Pharma is pleased to announce that the Data Safety Monitoring Board (DSMB) has completed its second safety review of a cohort of the first 50 patients of the SEALS study and confirmed a good safety profile of NX210c. |
| 2025-07-28 | Axoltis Pharma | Results SEALS First DSMB positive review axoltis.com ↗
The Data Safety Monitoring Board (DSMB), composed of 3 independent experts, reviewed safety data on a first cohort of ALS patients and concluded that safety was good and NX210c well tolerated. |
| 2024-08-04 | Axoltis Pharma | Results GRC Conference 2024 – Barriers of the CNS axoltis.com ↗
NX210c induced a transient increase in occludin protein expression after 24h treatment (+37% at 100 µM; western-blot) in mouse EC. |
| 2024-05-22 | Axoltis Pharma | Results WFNR 2024 – Spinal Cord Injury axoltis.com ↗
NX210c drug candidate peptide promotes functional recovery and repair in a rat cervical clip-compression model of spinal cord injury |
| 2024-05-22 | Axoltis Pharma | Results WFNR 2024 – Amyotrophic Lateral Sclerosis axoltis.com ↗
A dose-dependent improvement of motor performances was observed in SOD1 mice treated with NX210c. |
| 2024-05-04 | Axoltis Pharma | Results AD/PD 2024 – Parkinson Disease (BBB restoration) axoltis.com ↗
Accordingly, NX210c decreased by half the permeability to a 40 kDa-FITC-Dextran and increased transendothelial electrical resistance (TEER). |
| 2024-04-18 | Axoltis Pharma | Results AD/PD 2024 – Parkinson Disease (Neuroprotection) axoltis.com ↗
NX210c reduced α-synuclein-induced neurite network retraction, neuronal death and microglial activation in dopaminergic neuron cultures, when applied in parallel of α-synuclein regardless of the dose used. |
| 2023-12-12 | Axoltis Pharma | Results Axoltis Pharma presents promising results from phase 1b clinical trial of innovative drug candidate for neurodegenerative diseases axoltis.com ↗ |
| 2022-11-12 | Axoltis Pharma | Results Neuroscience 2022 – Spinal Cord Injury axoltis.com ↗
NX210c: subcommissural organ-spondin-derived peptide enhances behavioural functional recovery and tissue preservation in cervical traumatic spinal cord injury |
| 2022-07-09 | Axoltis Pharma | Results FENS 2022 – Neurotransmission axoltis.com ↗
Subcommissural organ-spondin-derived peptide (NX210c) promotes glutamatergic receptor-related synaptic transmission and signaling in the mouse CNS |
| 2022-05-29 | Axoltis Pharma | Results Brain & Brain Pet 2022 axoltis.com ↗
While OGD causes synaptic depression, concurrent administration of NX210c improves recovery. |
All press releases naming this drug 19 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NX210c | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06365216 ↗ |
| Route | Intravenous | “multiple intravenous infusions of NX210c” NCT05827653 ↗ |